What is HC Wainwright’s Forecast for JSPR FY2029 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($10.81) per share for the year. HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

A number of other equities research analysts also recently commented on JSPR. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock. Royal Bank of Canada reduced their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, JMP Securities reissued a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics presently has an average rating of “Buy” and a consensus price target of $70.88.

Jasper Therapeutics Trading Down 60.5 %

NASDAQ:JSPR opened at $6.99 on Friday. The company has a market capitalization of $104.86 million, a P/E ratio of -1.47 and a beta of 2.18. Jasper Therapeutics has a 12 month low of $6.61 and a 12 month high of $31.01. The business’s 50-day moving average is $21.66 and its 200 day moving average is $20.37.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the period. Wolff Wiese Magana LLC purchased a new stake in shares of Jasper Therapeutics in the third quarter valued at approximately $59,000. MetLife Investment Management LLC boosted its holdings in shares of Jasper Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the period. Rhumbline Advisers purchased a new stake in shares of Jasper Therapeutics in the second quarter valued at approximately $300,000. Finally, Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics in the third quarter valued at approximately $251,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.